AstraZeneca/Ionis’s Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks
US FDA Approval Pending With Decision Due In December
Executive Summary
Patients continued to improve across all three Phase III NEURO-TTRansform co-primary endpoints with 29 more weeks of treatment, setting up eplontersen to challenge Alnylam’s Amvuttra.